Patent
أعرض في EDS

Antigen-specific tolerance and compositions for induction of same

التفاصيل البيبلوغرافية
العنوان: Antigen-specific tolerance and compositions for induction of same
Patent Number: 11246,943
تاريخ النشر: February 15, 2022
Appl. No: 16/584691
Application Filed: September 26, 2019
مستخلص: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
Inventors: École Polytechnique Fédérale de Lausanne (EPFL) (Lausanne, CH)
Assignees: École Polytechnique Fédérale de Lausanne (EPFL) (Lausanne, CH)
Claim: 1. A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising: an antigen to which tolerance is desired; wherein the antigen is selected from the group consisting of an immunogenic fragment of desmoglein 3, an immunogenic fragment of desmoglein 1, and an immunogenic fragment of desmoglein 4; an erythrocyte-binding moiety, wherein the erythrocyte-binding moiety has the ability to non-covalently, specifically bind an exterior erythrocyte surface in situ in blood, wherein the erythrocyte-binding moiety presents said antigen to the immune system of a human, wherein the erythrocyte-binding moiety comprises an antibody fragment, wherein the antigen to which tolerance is desired is recombinantly fused or chemically conjugated to the erythrocyte-binding moiety, and wherein, upon administration to a human in which tolerance to the antigen is desired: the composition binds to CD45 negative cells, but not to CD45 positive cells, and the composition reduces, fails to induce, or prevents inflammatory responses in antigen-specific T cells as compared to when the human is exposed to the antigen separately from the composition, and the composition reduces the number of resident lymph node and spleen cells expressing interferon-gamma (IFNγ), as compared to the number of resident lymph node and spleen cells expressing IFNγ when the human is exposed to the antigen separately from the composition.
Claim: 2. The composition of claim 1 , wherein the antibody fragment is directed against glycophorin A, wherein the erythrocyte-binding moiety is derived from a 10F7 clone, wherein the administration of the composition ameliorates pemphigus vulgaris.
Claim: 3. The composition of claim 1 , wherein the erythrocyte-binding moiety specifically binds to a biomolecule selected from the group consisting of Band 3 (CD233), aquaporin-1, Glut-1, Kidd antigen, RhAg/Rh50 (CD241), Rh (CD240), Rh30CE (CD240CE), Rh30D (CD240D), Kx, glycophorin A, glycophorin B (CD235b), glycophorin C (CD235c), glycophorin D (CD235d), Kell (CD238), Duffy/DARCi (CD234), CR1 (CD35), DAF (CD55), Globoside, CD44, ICAM-4 (CD242), Lu/B-CAM (CD239), XG1/XG2 (CD99), EMMPRIN/neurothelin (CD147), JMH, Glycosyltransferase, Cartwright, Dombrock, C4A/CAB, Scianna, MER2, stomatin, BA-1 (CD24), GPIV (CD36), CD108, CD139, and H antigen (CD173).
Claim: 4. The composition of claim 1 , wherein the erythrocyte-binding moiety is affinity matured, wherein the erythrocyte-binding moiety does not specifically bind to other blood components, wherein the other blood components comprises blood proteins, albumin, fibronectin, platelets, and white blood cells, wherein the binding of the erythrocyte-binding moiety to the erythrocyte cell surface does not alter cell morphology, wherein there is no cytoplasmic translocation of the composition upon binding of the erythrocyte-binding moiety to the erythrocyte cell surface, and wherein the binding of the erythrocyte-binding moiety to the erythrocyte cell surface does not cause the erythrocytes to become apoptotic.
Claim: 5. The composition of claim 1 , wherein the erythrocyte-binding moiety comprises an scFv, a divalent scFv, a diabody, a triabody, or a tetrabody.
Claim: 6. The composition of claim 1 , wherein the erythrocyte-binding moiety is derived from a 10F7 clone.
Claim: 7. The composition of claim 1 , wherein the antibody fragment is affinity matured.
Claim: 8. A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising: an antigen recombinantly fused or chemically conjugated with an erythrocyte-binding moiety; said antigen being recognizable by an immune system of a subject, the immune system of the subject being able to respond to the antigen with an unwanted immune response, wherein the antigen is a food antigen; wherein said erythrocyte-binding moiety comprises a peptide; wherein upon administration of the composition, said erythrocyte-binding moiety non-covalently and specifically binds a human erythrocyte in situ in blood and presents said antigen to the immune system of the subject; wherein the erythrocyte-binding moiety does not specifically bind to other blood components, wherein the other blood components comprises blood proteins, albumin, fibronectin, platelets, and white blood cells; and wherein said composition elicits a tolerogenic response upon administration to said subject.
Claim: 9. The composition of claim 8 , wherein the erythrocyte-binding moiety comprises an antibody fragment, wherein the antibody fragment is derived from a 10F7 clone, and wherein the antibody fragment has undergone affinity maturation.
Claim: 10. The composition of claim 8 , wherein the erythrocyte-binding moiety is chemically conjugated to the antigen.
Claim: 11. The composition of claim 8 , wherein the erythrocyte-binding moiety is fused to the antigen via recombinant DNA technology.
Claim: 12. A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising: one or more antigens fused or chemically conjugated with an erythrocyte-binding moiety; wherein said one or more antigens is associated with an auto-immune disease; wherein said one or more antigens being recognizable by an immune system of a subject, the immune system of the subject being able to respond to or previously having responded to the one or more antigens with an unwanted immune response, said erythrocyte-binding moiety having the ability to non-covalently, specifically bind an erythrocyte surface in situ in blood and present said one or more antigens to the immune system of the subject, wherein said erythrocyte-binding moiety comprises an antibody fragment, wherein, upon administration to a human in which tolerance to the antigen is desired: the composition binds to CD45 negative cells, but not to CD45 positive cells, and the composition reduces, fails to induce, or prevents inflammatory responses in antigen-specific T cells as compared to when the human is exposed to the antigen separately from the composition, and the composition reduces the number of resident lymph node and spleen cells expressing interferon-gamma (IFNγ), as compared to the number of resident lymph node and spleen cells expressing IFNγ when the human is exposed to the antigen separately from the composition.
Claim: 13. The composition of claim 12 , wherein the erythrocyte-binding moiety has the ability to bind Band 3 (CD233), glycophorin-A, glycophorin B (CD235b), glycophorin C(CD235c), or glycophorin D (CD235d) with an affinity generating a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.
Claim: 14. The composition of claim 12 , comprising two or more antigens selected from the group consisting of an immunogenic fragment of desmoglein 3, an immunogenic fragment of desmoglein 1, and an immunogenic fragment of desmoglein 4.
Claim: 15. The composition of claim 14 , wherein said antigens are conjugated to a multimeric branched polymer.
Claim: 16. The composition of claim 14 , wherein the erythrocyte-binding moiety is derived from a 10F7 clone, and wherein the erythrocyte-binding moiety is affinity-matured.
Claim: 17. The composition of claim 12 , wherein the erythrocyte-binding moiety is fused via a linker, to the N- or C-terminus of the one or more antigens.
Claim: 18. The composition of claim 16 , wherein the linker is a peptide, a polymer, an aptamer, a nucleic acid, or a particle.
Patent References Cited: 4671958 June 1987 Rodwell et al.
4741900 May 1988 Alvarez et al.
4859449 August 1989 Mattes
4867973 September 1989 Goers et al.
4950738 August 1990 King et al.
5086002 February 1992 Hillyard et al.
5140104 August 1992 Coughlin et al.
5156840 October 1992 Goers et al.
5162512 November 1992 King et al.
5227165 July 1993 Domb et al.
5227293 July 1993 Stengelin et al.
5346696 September 1994 Kim et al.
5358857 October 1994 Stengelin et al.
5470570 November 1995 Taylor et al.
5487890 January 1996 Taylor et al.
5681571 October 1997 Holmgren et al.
5698679 December 1997 Nemazee et al.
5718915 February 1998 Virtanen et al.
5879679 March 1999 Taylor et al.
5885808 March 1999 Spooner et al.
5886143 March 1999 Theodore et al.
5948639 September 1999 Gimeno et al.
5985826 November 1999 Theodore et al.
5994104 November 1999 Anderson et al.
5997861 December 1999 Virtanen et al.
6022564 February 2000 Takechi et al.
6090925 July 2000 Woiszwillo et al.
6120770 September 2000 Adams et al.
6153203 November 2000 Holmgren et al.
6217869 April 2001 Meyer et al.
6224794 May 2001 Amsden et al.
6264950 July 2001 Staerz
6322796 November 2001 Holmgren et al.
6365163 April 2002 Holmgren et al.
6379699 April 2002 Virtanen et al.
6488927 December 2002 Muzykantov et al.
6512103 January 2003 Dairaghi et al.
6562347 May 2003 Kwak et al.
6703488 March 2004 Burton et al.
6737057 May 2004 Zaghouani et al.
6814964 November 2004 Virtanen et al.
6905688 June 2005 Rosen et al.
6953675 October 2005 Leung et al.
7041287 May 2006 Muzykantov et al.
7132475 November 2006 Hubbel et al.
7144569 December 2006 Anderson et al.
7148329 December 2006 Figdor et al.
7172760 February 2007 Muzykantov et al.
7175988 February 2007 Roschke et al.
7192582 March 2007 Hudson et al.
7285642 October 2007 Figdor et al.
7420040 September 2008 Young et al.
7420041 September 2008 Young et al.
7541180 June 2009 Valiante et al.
7585508 September 2009 Prendergast
7612180 November 2009 Goldenberg et al.
7704943 April 2010 Griffin et al.
7704964 April 2010 Delcayre et al.
7786267 August 2010 Rawski et al.
7811809 October 2010 Heyduk et al.
7837997 November 2010 Muzykantov et al.
7884190 February 2011 Cohen et al.
7888460 February 2011 Anderson et al.
7892743 February 2011 Owen et al.
7932294 April 2011 Satyam
7994283 August 2011 Valiante et al.
8007805 August 2011 George et al.
8021689 September 2011 Reddy et al.
8057798 November 2011 Rawski et al.
8058400 November 2011 Figdor et al.
8058406 November 2011 Mi et al.
8105599 January 2012 Figdor et al.
8236934 August 2012 Banchereau et al.
8252902 August 2012 Barbas et al.
8273357 September 2012 Hacohen et al.
8277812 October 2012 Iannacone et al.
8318912 November 2012 Simon
8323696 December 2012 Hubbel et al.
8329144 December 2012 Anderson et al.
8333973 December 2012 Muzykantov
8343497 January 2013 Shi et al.
8343498 January 2013 Alexis et al.
8425910 April 2013 Mi et al.
8449888 May 2013 Rawski et al.
8507237 August 2013 Hermet et al.
8518410 August 2013 Rawski et al.
8551476 October 2013 Mi et al.
8562998 October 2013 Shi et al.
8580253 November 2013 Rubin-Bejerano et al.
8586052 November 2013 Rawski et al.
8591905 November 2013 von Andrian et al.
8592364 November 2013 Swartz et al.
8613903 December 2013 Goldenberg et al.
8617823 December 2013 Rubin-Bejerano et al.
8637028 January 2014 Alexis et al.
8673293 March 2014 Martin et al.
8685408 April 2014 Tartour et al.
8722047 May 2014 Goldenberg et al.
8728481 May 2014 Banchereau et al.
8859629 October 2014 van Delft et al.
8889140 November 2014 Lee et al.
8906381 December 2014 Iannacone et al.
8932595 January 2015 Iannacone et al.
8961991 February 2015 Zurawski et al.
8992917 March 2015 Goldenberg et al.
9005903 April 2015 Rubin-Bejerano et al.
9066984 June 2015 Mi et al.
9102730 August 2015 Zurawski et al.
9102734 August 2015 Zurawski et al.
9187561 November 2015 Goldenberg et al.
9216156 December 2015 Fleury et al.
9233072 January 2016 Alexis et al.
9234040 January 2016 Zurawski et al.
9260692 February 2016 Martin et al.
9308280 April 2016 Shi et al.
9326939 May 2016 Paulson et al.
9416186 August 2016 Zurawski et al.
9439859 September 2016 Alexis et al.
9453074 September 2016 Oh et al.
9457047 October 2016 Rubin-Bejerano et al.
9474717 October 2016 von Andrian et al.
9517257 December 2016 Hubbell
9518087 December 2016 Hubbell et al.
9522183 December 2016 Paulson et al.
9539210 January 2017 von Andrian et al.
9561272 February 2017 Thomas et al.
9688991 June 2017 Levy et al.
9751945 September 2017 Ploegh et al.
9814780 November 2017 Hubbell
9850296 December 2017 Hubbell
9878048 January 2018 Hubbell et al.
9901645 February 2018 Hubbell et al.
9901646 February 2018 Hubbell et al.
10046056 August 2018 Hubbell et al.
10800838 October 2020 Hubbell et al.
10821157 November 2020 Hubbell et al.
10919963 February 2021 Hubbell et al.
10940209 March 2021 Hubbell et al.
10946079 March 2021 Hubbell et al.
10953101 March 2021 Hubbell et al.
2002/0004037 January 2002 Koteliansky et al.
2002/0038002 March 2002 Zaghouani
2002/0081298 June 2002 Zaghouani
2002/0103343 August 2002 Taylor et al.
2002/0187131 December 2002 Hawiger et al.
2002/0193572 December 2002 Leung et al.
2003/0022826 January 2003 Haynes
2003/0082643 May 2003 Hudson et al.
2003/0103967 May 2003 Zaghouani
2003/0104045 June 2003 Virtanen et al.
2003/0175921 September 2003 Barbas et al.
2003/0190676 October 2003 Barbas et al.
2003/0211078 November 2003 Heavner
2004/0052815 March 2004 Lycke
2004/0077843 April 2004 Burton et al.
2004/0146948 July 2004 Britton et al.
2004/0147721 July 2004 Valiante
2004/0185057 September 2004 Kirkby et al.
2004/0197314 October 2004 Delcayre et al.
2004/0258688 December 2004 Hawiger et al.
2005/0031628 February 2005 George et al.
2005/0053579 March 2005 Galipeau et al.
2005/0113297 May 2005 Francois et al.
2005/0118168 June 2005 Figdor et al.
2005/0201973 September 2005 Virtanen et al.
2005/0203022 September 2005 Gotwals et al.
2005/0220804 October 2005 Figdor et al.
2005/0250936 November 2005 Oppermann et al.
2006/0034864 February 2006 Zaghouani
2006/0127929 June 2006 Swager et al.
2006/0153881 July 2006 Narum et al.
2006/0173168 August 2006 Carlock et al.
2006/0178299 August 2006 Anderson et al.
2006/0257412 November 2006 Bowdish et al.
2006/0280679 December 2006 Bowdish et al.
2007/0059794 March 2007 Ideno et al.
2007/0111222 May 2007 Chasin et al.
2007/0122409 May 2007 Zaghouani
2007/0190615 August 2007 Cohen et al.
2007/0218053 September 2007 Zaghouani
2008/0031899 February 2008 Reddy et al.
2008/0131428 June 2008 Young et al.
2008/0160041 July 2008 Figdor et al.
2008/0175971 July 2008 Anderson et al.
2008/0178299 July 2008 Merkle et al.
2008/0206262 August 2008 Banchereau et al.
2008/0213267 September 2008 Young et al.
2008/0227707 September 2008 Carlock et al.
2008/0233143 September 2008 Jackson et al.
2008/0241170 October 2008 Zurawski et al.
2008/0254044 October 2008 Zurawski
2008/0261262 October 2008 Godfrin
2008/0274092 November 2008 Godfrin et al.
2008/0305104 December 2008 Young et al.
2008/0318852 December 2008 Anderson et al.
2009/0004218 January 2009 Hacohen et al.
2009/0017039 January 2009 Mi et al.
2009/0123467 May 2009 Bedi et al.
2009/0130104 May 2009 Muzykantov et al.
2009/0142263 June 2009 Young et al.
2009/0149656 June 2009 Singaram et al.
2009/0181011 July 2009 Zaghouani
2009/0191118 July 2009 Young et al.
2009/0202622 August 2009 Fleury et al.
2009/0269285 October 2009 Anderson et al.
2009/0280132 November 2009 Zaghouani
2009/0317381 December 2009 Plaut et al.
2009/0324538 December 2009 Wong et al.
2010/0003266 January 2010 Simon
2010/0003338 January 2010 Hubbell et al.
2010/0015131 January 2010 Mi et al.
2010/0055189 March 2010 Hubbell et al.
2010/0092425 April 2010 Von Andrian et al.
2010/0098718 April 2010 Valiante
2010/0129392 May 2010 Shi et al.
2010/0129439 May 2010 Alexis et al.
2010/0129820 May 2010 Kool et al.
2010/0222407 September 2010 Segura et al.
2010/0233251 September 2010 Von Andrian et al.
2010/0239575 September 2010 Banchereau et al.
2010/0285015 November 2010 Muzykantov et al.
2010/0291080 November 2010 Lee et al.
2010/0291082 November 2010 Zurawski
2010/0297114 November 2010 Zurawski
2010/0310612 December 2010 DuFour et al.
2010/0316620 December 2010 Bourgeaux et al.
2010/0322929 December 2010 Zurawski et al.
2010/0330115 December 2010 Zurawski et al.
2011/0014171 January 2011 Bourgeaux et al.
2011/0033426 February 2011 Martin et al.
2011/0044912 February 2011 Anderson et al.
2011/0045049 February 2011 Rubin-Bejerano et al.
2011/0064709 March 2011 Miller et al.
2011/0064754 March 2011 Taylor et al.
2011/0082075 April 2011 Prendergast
2011/0091493 April 2011 Mohamadzadeh et al.
2011/0105379 May 2011 Shulman et al.
2011/0123536 May 2011 Chermann et al.
2011/0143994 June 2011 Lycke
2011/0177532 July 2011 Rubin-Bejerano et al.
2011/0200632 August 2011 Jackson et al.
2011/0206759 August 2011 Swartz et al.
2011/0268804 November 2011 Shi et al.
2011/0268805 November 2011 Alexis et al.
2011/0293644 December 2011 Anderson et al.
2011/0311542 December 2011 Mi et al.
2012/0004643 January 2012 Zurawski et al.
2012/0009140 January 2012 Godfrin et al.
2012/0014960 January 2012 Mi et al.
2012/0027808 February 2012 Iannacone
2012/0039989 February 2012 Hubbel et al.
2012/0058180 March 2012 Kren et al.
2012/0076831 March 2012 Miller et al.
2012/0087890 April 2012 Iannacone et al.
2012/0107301 May 2012 Bowdish et al.
2012/0121570 May 2012 Godfrin
2012/0121592 May 2012 Oh et al.
2012/0128635 May 2012 Gregory et al.
2012/0129210 May 2012 Bourgeaux et al.
2012/0178139 July 2012 Hubbel et al.
2012/0207745 August 2012 Godfrin et al.
2012/0237513 September 2012 Zurawski et al.
2012/0276095 November 2012 Langermann et al.
2012/0282281 November 2012 Banchereau et al.
2013/0004427 January 2013 El-Sayed et al.
2013/0022634 January 2013 Lycke
2013/0053543 February 2013 Davis et al.
2013/0059299 March 2013 Parr et al.
2013/0071413 March 2013 Simon
2013/0078216 March 2013 Dunlevy et al.
2013/0078267 March 2013 Anderson et al.
2013/0101463 April 2013 Mambrini et al.
2013/0115230 May 2013 Simon
2013/0129790 May 2013 Alexis et al.
2013/0164364 June 2013 Paulson et al.
2013/0171074 July 2013 Barbas et al.
2013/0171233 July 2013 Paulson et al.
2013/0236533 September 2013 Von Andrian et al.
2013/0287810 October 2013 Mohamadzadeh et al.
2013/0287857 October 2013 Von Andrian et al.
2013/0295120 November 2013 Zurawski et al.
2013/0318648 November 2013 Anderson et al.
2013/0323786 December 2013 Mi et al.
2013/0336991 December 2013 Mi et al.
2014/0037736 February 2014 Shi et al.
2014/0079728 March 2014 Jackson et al.
2014/0127198 May 2014 Zurawski et al.
2014/0127301 May 2014 Alexis et al.
2014/0134168 May 2014 Zurawski et al.
2014/0199315 July 2014 Mi et al.
2014/0205630 July 2014 Tartour
2014/0212445 July 2014 Martin et al.
2014/0227268 August 2014 Banchereau et al.
2014/0234344 August 2014 Banchereau et al.
2014/0308238 October 2014 Rubin-Bejerano et al.
2014/0314865 October 2014 Adrian et al.
2014/0377291 December 2014 Fischbach et al.
2015/0104478 April 2015 Lee et al.
2015/0166659 June 2015 Goldenberg et al.
2015/0191730 July 2015 Levy et al.
2015/0250862 September 2015 Cantor et al.
2015/0299329 October 2015 Zurawski et al.
2015/0307545 October 2015 Jackson et al.
2016/0015821 January 2016 Hubbell et al.
2016/0022792 January 2016 Zurawski et al.
2016/0024212 January 2016 Goldenberg et al.
2016/0031988 February 2016 Zurawski et al.
2016/0058792 March 2016 Quintana et al.
2016/0060324 March 2016 Paulson et al.
2016/0060358 March 2016 Hay
2016/0083468 March 2016 Mi et al.
2016/0108096 April 2016 Thompson et al.
2016/0243248 August 2016 Hubbell et al.
2016/0346384 December 2016 Porcelli et al.
2016/0354453 December 2016 Hubbell et al.
2016/0375126 December 2016 Oh et al.
2017/0007708 January 2017 Hubbell et al.
2017/0020926 January 2017 Mata-Fink et al.
2017/0066825 March 2017 Hubbell et al.
2017/0066828 March 2017 Goldenberg et al.
2017/0121379 May 2017 Zhang et al.
2017/0137513 May 2017 Vallera et al.
2017/0252417 September 2017 Irvine et al.
2017/0296636 October 2017 Hubbell et al.
2017/0320933 November 2017 Mannie
2017/0326213 November 2017 Jajosky et al.
2018/0000916 January 2018 Zurawski et al.
2018/0094071 April 2018 Zurawski et al.
2018/0100011 April 2018 Hubbell et al.
2018/0104284 April 2018 Wallecha et al.
2018/0117171 May 2018 Mooney et al.
2018/0271986 September 2018 Hubbell et al.
2018/0303951 October 2018 Hubbell et al.
2019/0382479 December 2019 Hubbell et al.
2020/0101146 April 2020 Hubbell et al.
2020/0121762 April 2020 Hubbell et al.
2020/0129601 April 2020 Hubbell et al.
2020/0129625 April 2020 Hubbell et al.
2020/0129629 April 2020 Hubbell et al.
101750244 June 2010
0119650 September 1984
0175617 October 1991
0088695 June 1992
0173629 June 1992
0480041 June 1993
0308208 December 1993
0251455 May 1994
0294294 May 1995
0789715 August 1997
0808366 November 1997
0722340 April 1998
0505357 March 1999
0602290 August 1999
0978564 February 2000
1012308 June 2000
630407 August 2000
1046651 October 2000
1301541 April 2003
0743856 July 2003
1370588 December 2003
1292621 September 2006
1838734 October 2007
1853313 November 2007
1028978 January 2008
1086137 June 2008
1938836 July 2008
1440156 August 2008
1619208 October 2008
1996701 December 2008
1045861 March 2009
2125012 December 2009
1516881 June 2010
2238986 October 2010
2315779 May 2011
1417229 June 2011
2344187 July 2011
2394657 December 2011
2394661 December 2011
2406290 January 2012
2428226 March 2012
2478917 July 2012
2066294 October 2012
2527363 November 2012
2598120 June 2013
2618817 July 2013
2620157 July 2013
2630967 August 2013
1904104 September 2013
1991564 September 2013
2115129 November 2013
2684889 January 2014
1443963 May 2014
1664270 May 2014
2115002 August 2014
1605974 November 2014
1850832 December 2014
2114985 December 2014
2283358 April 2015
2213742 January 2016
2982695 February 2016
2983791 February 2016
2989123 March 2016
2346528 April 2016
2406286 May 2016
2205273 September 2016
3091034 November 2016
2406288 December 2016
2406289 February 2017
2217269 April 2017
2344186 April 2017
2630966 April 2017
S5742852 March 1982
S59173762 October 1984
2003-519619 June 2003
2004-526452 September 2004
2007-510915 April 2007
2007-312776 December 2007
2009-505049 February 2009
2009-060894 March 2009
2009-149664 July 2009
2013-516967 May 2013
2018-072431 August 2018
WO 1991/008770 June 1991
WO 1992/05801 April 1992
WO 1992/22310 December 1992
WO 1995/06737 March 1995
WO 1995/22977 August 1995
WO 1996/023882 August 1996
WO 1996/040245 December 1996
WO 1998/06737 February 1998
WO 1999/38536 May 1999
WO 1999/036437 July 1999
WO 1999/38536 August 1999
WO 00/01732 January 2000
WO 2000/074717 December 2000
WO 2001/022995 April 2001
WO 2001/025793 April 2001
WO 2002/004522 January 2002
WO 2002/072799 September 2002
WO 2002/083262 October 2002
WO 2002/102407 December 2002
WO 2003/064464 August 2003
WO 2003/066820 August 2003
WO 2003/104273 December 2003
WO 2004/034966 April 2004
WO 2004/035619 April 2004
WO 2004/045520 June 2004
WO 2004/098645 November 2004
WO 2005/045436 May 2005
WO 2005/105129 November 2005
WO 2006/002382 January 2006
WO 2006/016247 February 2006
WO 2006/093524 September 2006
WO 2007/008300 January 2007
WO 2007/017556 February 2007
WO 2007/095748 August 2007
WO 2007/097934 August 2007
WO 2007/098254 August 2007
WO 2007/099387 September 2007
WO 2007/099446 September 2007
WO 2007/101698 September 2007
WO 2007/150020 December 2007
WO 2008/063849 May 2008
WO 2009/018500 February 2009
WO 2009/019317 February 2009
WO 2009/056332 May 2009
WO 2009/078796 June 2009
WO 2009/086552 July 2009
WO 2009/120893 October 2009
WO 2010/042870 April 2010
WO 2010/045518 April 2010
WO 2010/060155 June 2010
WO 2010/076517 July 2010
WO 2010/085509 July 2010
WO 2011/012715 February 2011
WO 2011/051346 May 2011
WO 2011/086143 July 2011
WO 2011/092715 August 2011
WO 2011/112482 September 2011
WO 2012/021512 February 2012
WO 2012/057671 May 2012
WO 2012/083185 June 2012
WO 2012/112690 August 2012
WO 2012/167088 December 2012
WO 2013/121296 August 2013
WO 2013/160865 October 2013
WO 2014/011465 January 2014
WO 2014/023709 February 2014
WO 2014/052545 April 2014
WO 2014/135528 September 2014
WO 2014/169255 October 2014
WO 2015/140648 September 2015
WO 2015/157595 October 2015
WO 2015/171863 November 2015
WO 2015/175957 November 2015
WO 2016/022971 February 2016
WO 2016/044655 March 2016
WO 2016/044661 March 2016
WO 2016/070050 May 2016
WO 2016/210447 December 2016
WO 2017/015141 January 2017
WO 2017/023779 February 2017
WO 2017/025889 February 2017
WO 2017/041053 March 2017
WO2017/044308 March 2017
WO 2017/046652 March 2017
WO 2017/058996 April 2017
WO 2017/066484 April 2017
WO 2017/109134 June 2017
WO 2017/112899 June 2017
WO 2017/139498 August 2017
WO 2017/139787 August 2017
WO 2017/192785 November 2017
WO 2017/192786 November 2017
WO 2018/232176 December 2018
WO 2019/098682 May 2019
WO 2019/191079 October 2019
WO 2019/0215590 November 2019
WO 2021/053589 March 2021
Other References: Zaitsev et al. (Sergei Zaitsev, Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis (Year: 2010). cited by examiner
Desmoglein as a Target in Skin Disease and Beyond Masayuki Amagai (Year: 2012). cited by examiner
“EPFL School of Life Sciences—Annual Report SV 2011,” 156 Pages (Dec. 31, 2011 ). cited by applicant
“SubName: Full=Phosphate ABC Transporter, Inner Membrane Subunit PstC;”, XP002717162, Retrieved From EBI Accession No. UNIPROT:C7QKI6, Database Accession No. C7QKI6 (Oct. 13, 2009). cited by applicant
“SubName: Full=Putative Integron Gene Cassette Protein; Flags: Fragment;”, XP002717159, Retrieved From EBI Accession No. UNIPROT:BOBITO, Database Accession No. BOBITO (Feb. 26, 2008). cited by applicant
“SubName: Full=Putative Transcriptional Regulator, ArsR Family;”, XP002717163, Retrieved From EBI Accession No. UNIPROT:D2RZT2, Database Accession No. D2RZT2 (Mar. 2, 2010). cited by applicant
“SubName: Full=Putative Uncharacterized Protein;”, XP002717158, Retrieved From EBI Accession No. UNIPROT: CONJEO, Database Accession No. CONJEO (May 5, 2009). cited by applicant
“SubName: Full=Putative Uncharacterized Protein;”, XP002717160, Retrieved From EBI Accession No. UNIPROT:B9PUPO, Database Accession No. B9PUPO (Mar. 24, 2009). cited by applicant
“SubName: Full=Uncharacterized Protein;”, XP002717157, Retrieved From EBI Accession No. UNIPROT:B5E9K2 Database Accession No. B5E9K2 (Oct. 14, 2008). cited by applicant
Ahmed et al., “Carbohydrate-based materials for targeted delivery of drugs and genes to the liver.” Nanomedicine (Lond.) (205) 10(14), 2263-2288. cited by applicant
Albert et al., “Immature dendritic cells phagocytose apoptotic cells Via vl35 and CD36, and cross-present antigens to cytotoxic T lymphocytes,” Journal of Experinmental Medicine, vol. 188(7): 1359-1368 (Oct. 5, 1998). cited by applicant
Andre et al., “Determination of modulation of ligand properties of synthetic complex-type biantennary N-glycans by introduction of bisecting GIcNAc in silico, in vitro and in vivo” Eur. J. Biochem. 2004;271(1):118-134. cited by applicant
Arnaboldi et al., “Suppression of Th 1 and Th17, but not Th2, responses in a CD8+ T cell-mediated model of oral tolerance,” Mucosal Immunology, vol. 2(5):427-438 (Sep. 2009). cited by applicant
Bailon et al., “Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon -2a for the treatment of hepatitis C,” Bioconjugate Chemistry, vol. 12(2):195-202 (2001). cited by applicant
Bielekova et al., “Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4 T Cells in Multiple Sclerosis,” J Immunol 2004; 172:3893-3904. cited by applicant
Bigbee et al.,“Binding specificities of eight monoclonal antibodies to human glycophorin A—studies with McM, and MkEn(UK) variant human erythrocytes and M- and MNv-type chimpanzee erythrocytes,” Dec. 1, 1984, J. Immunol., 133(6): 3149-3155 (1984). cited by applicant
Blancher et al., “Reactivity of anti-glycophorin monoclonal antibodies (Mabs) in tests with red cells of non-human primates,” Jan. 1, 1997, Transfus Clin Biol 4, 81-85 (1997). cited by applicant
Brack et al., “Tumor-ta rgeting properties of novel antibodies specific to the large isoform of tenascin-C,” Clinic Cancer Research, vol. 12(10):3200-3208 (May 15, 2006). cited by applicant
Bursch et al., “Langerhans cells are not required for the COB T cell response to epidermal self-antigens,” Journal of Immunology, vol. 182(8):4657-4664 (Apr. 15, 2009). cited by applicant
Cao et al., “Molecular Beacon Aptamers for Protein Monitoring in Real-Time and in Homogeneous Solutions,” Current Proteomics, 2:31-401, (2005). cited by applicant
Chasis et al., “Signal Transduction by Glycophorin A: Role of Extracellula Rand Cytoplasmic Domains in a Modulatable Process”, The Journal of Cell Biology, 107:1351-1357, (Oct. 1988). cited by applicant
Chiarantini et al., “Red Blood Cells as DeliveRy System for Recombinant HSV-1 Glycoprotein B: Immunogenicity and Protection in Mice,” Vaccine, 15(3):276-280, (1997). cited by applicant
Ciccocioppo, R. et al., “The immune recognition of gluten in coeliac disease”, British Society for Immunology, Clinical and Experimental Immunology, Feb. 1, 2005, pp. 408-416. cited by applicant
Coulstock et al., “Liver-targeting of interferon-alpha with tissue-specific domain antibodies” PLOS ONE, Public Library of Science, US, vol. 8, No. 2, Jan. 1, 2013. cited by applicant
Craig et al., “Processing of C3b-Opsonized Immune Complexes Bound to Non-Complement Receptor 1 Sites on Red Cells: Phagocytosis, Transfer and Associations with CR1,” J. Immunol. cited by applicant
Crispe et al., “Cellular and molecular mechanisms of liver tolerance,” Immunol Rev., 213: 101-118 (2006). cited by applicant
Dane et al., “Isolation of cell specific peptide ligands using fluorescent bacterial display libraries-” Journal of Immunological Methods, vol. 309(1-2):120-129, (Jan. 2006). cited by applicant
Darrah et al., “IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform,” Journal of Experimental Medicine, vol. 207(7):1421-1433 (2010). cited by applicant
Dennis et al.,“Albumin Binding as a General Strategy forlmproving the Pha rmacokinetics of Proteins-” Journal of Biological Chemistry, vol. 277(38):35035-35043 (Sep. 20, 2002). cited by applicant
Devalapally et al., “Poly(ethylene oxide)-modified Poly(beta-amino ester) Nanoparticles as a pH-sensitive System for Tumor-targeted Delivery of Hydrophobic Drugs: Part 3. Therapeutic Efficacy and Safety Studies in Ovarian CanceRXenog Raft Model,” Cancer Chemotherapy Pharmacology, 59:477-484, (2007). cited by applicant
Dhalluin et al.,“Structural and biophysical characterization of the 40 kDa PEG-interferon- 2a and its individual positional isomers,” Bioconjugate Chemistry, vol. 16(3):504-517 (2005). cited by applicant
Di Lorenzo et al., “Translational Mini-Review Series on Type 1 Diabetes: Systemic analysis of T cell epitopes in autoimmune diabetes,” 2007, Clin Exp Immunol, vol. 148: 1-146. cited by applicant
Dienst et al., “Specific occlusion of mu rine and human tumor vasculature by VCAM-1-ta rgeted recombinant fusion proteins,” Journal ofThe National Cancer Institute, vol. 97(10):733-747, (2005). cited by applicant
Dieterich et al., “Identification of Tissue Transglutaminase as the Autoantigen of Celiac Disease,” Nature Medicine vol. 3 p. 797-801 (1997). cited by applicant
Dornmair Klaus et al.: “T-cell-mediated autoimmunity: Novel techniques to characterize autoreactive T-cell receptors”, American Journal of Pathology, vol. 163, No. 4, Oct. 2003 (Oct. 2003), pp. 1215-1226, ISSN: 0002-9440. cited by applicant
Ducan, R. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt. Advanced Drug Delivery Reviews 61 (2009) pp. 1131-1148. cited by applicant
Ferguson et al., “Armed response: How dying cells influence T-cell functions,” Immunology Review, vol. 241 (1 ):77-88 (May 2011 ). cited by applicant
Fife et al.,“Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L 1 pathway,” The Journal of Experimental Medicine, vol. 203(12):2737-2747, (Nov. 27, 2006). cited by applicant
Fishburn,“The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics,” Journal of Pharmaceutical Sciences vol. 97(10):4167-4183 (Oct. 10, 2008). cited by applicant
Folgori A et al: “A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and huamn sera”, EMBO (European Molecular Biology Organization) Journal, vol. 13, No. 9, May 1, 1994 (May 1, 1994), pp. 2236-2243, ISSN: 0261-4189. cited by applicant
Fonsatti et al.,“Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours,” Cardiovascular Research, vol. 86(1):12-19, (2010). cited by applicant
Gadaleta et al.,“Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors,” Critical Reviews in Oncology/Hematology, vol. 80:40-53 (2011). cited by applicant
Gao et al., “In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics-” Proceedings of the National Academy Sciences vol. 106(36):15231-15236 (Sep. 8, 2009). cited by applicant
Geng et al., “Site-directed conjugation of “clicked” glycopolymers for form glycoprotein mimics: binding to mammalian lectin and induction of immunological function.” J Am Chem Soc. Dec. 12, 2007;129(49):15156-63. cited by applicant
Getts et al., “Have We Overestimated the Benefit of Human(ized) Antibodies?” Landes Bioscience, 2(6):682-694, (Nov./Dec. 2010). cited by applicant
Getz et al., “Protease-Resistant Peptide Ligands From a Knottin Scaffold Library,” ACS Chemical Biology, 8 Pages, (May 26, 2011). cited by applicant
Godsel et al., “Prevention of autoimmune myocarditis through the induction of antigen-specific peripheral immune tolerance-” Circulation vol. 103(12):1709-1714 (2001). cited by applicant
Gorovits et al., “Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake,” Cancer Immunol Immunother (2013) 62:217-233. cited by applicant
Gorzelany et al., “Protein replacement therapies for rare diseases: a breeze for regulatory approval?” Science Translational Medicine 5, 178fs10 (2013). cited by applicant
Granoff et al., “A Novel Mimetic Antigen Eliciting Protective Antibody to Neisseria meningitidis” J Immunol 2001; 167:6487-6496. cited by applicant
Green et al.,“Immunogenic and tolerogenic cell death,” National Review of Immunology vol. 9(5):353-363, (May 2009). cited by applicant
Grimm et al., “Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens.” Scientific Reports, 5:159907. cited by applicant
Gupta et al., “Expression, purification, and characterization of an anti-RBCFab-p24 fusion protein for hemagglutination-based rapid detection of antibodies to HIV in whole blood.” Protein Expression and Purification 26 (2002) 162-170. cited by applicant
Hackel et al., “Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling,” Journal of Molecular Biolology, vol. 381 (5):1238-1252, (Sep. 19, 2008). cited by applicant
Hall et al., “Identification of peptide ligands facilitating nanopa rticle attachment toerythrocytes,” Biotechnology Progess, vol. 23(3):749-754 (2007). cited by applicant
Hasselberg et al., “ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization” The Journal of Immunology, Aug. 24, 2016. cited by applicant
Holz et al., “CD8+ T cell tolerance following antigen recognition on hepatocytes,” Journal of Autoimmunity, vol. 34 (1):15-22 (2010). cited by applicant
Huang et al., “Characterization of poly(ethylene glycol) and PEGylated products by LC/MS with postcolumn addition of amines,” Analytical Chemistry, vol. 81 (2):567-577 (Jan. 15, 2009). cited by applicant
Huang et al.,“Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature,” Science, vol. 275(5299):547-550 (Jan. 24, 1997). cited by applicant
Ichikawa et al., “Hepatic stellate cells function as regulatory bystanders,” Journal of Immunology, vol. 186 (10):5549-5555 (May 15, 2011). cited by applicant
“Integer”, Meriam-Webster, available online at https://www.merriam-webster.com/dictionary/integer, 12 pages (2019) (Year: 2019). cited by applicant
International Search Report and Written Opinion from corresponding PCT Application No. PCT/IB2013/000684, 12 pages, dated Jul. 9, 2013. cited by applicant
International Search Report and Written Opinion from corresponding PCT Application No. PCT/US2011/047078, 13 pages, dated May 1, 2012. cited by applicant
International Search Report for Application No. PCT/EP2014/054161 dated May 26, 2014. cited by applicant
Immunogenic, Definition of Immunogenic by Merriam-Webster, https://www.merriam-webster.com/dictionary/immunogenic[May 10, 2019 11:59:27 AM], retrieved on May 10, 2019, in 9 pages. cited by applicant
Janeway et al., “The complement system and innate immunity,” Immunology: the Immune System in Health and Disease, 5th Edition. New York: Garland Science (2001). cited by applicant
Janeway et al., Immuno Biology, 8th Edtition, Garland Science (2012). cited by applicant
Jewett et al., “Cu-free click cycloaddition reactions in chemical biology,” Chem Soc Rev. Apr. 2010; 39(4): 1272-1279. cited by applicant
Jones et al., “Localization of Pectic Galactan in Tomato Cell Walls Using a Monoclonal Antibody Specific to (1->4)-β-D-Galactan” Plant Physiol. 1997; 113:1405-1412. cited by applicant
Julyan et al “Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine” Journal of Controlled Release 57 (1999) pp. 281-290. cited by applicant
Keefe et al.,“Aptamers as therapeutics,” Nature Reviews Drug Discovery, vol. 9(7):537-550 (2010). cited by applicant
Kenrick et al., “Bacterial Display Enables Efficient and Quantitative Peptide Affinity Maturation,” Protein Engineering Design & Selection, vol. 23(1 ):9-17 (2010). cited by applicant
Khandelwal et al., “Assessment of survival of aging erythrocyte in circulation and attendant changes in size and CD147 expression by a novel two step biotinylation method,” Experimental Gerontology, vol. 41 (9):855-861 (Aug. 4, 2006). cited by applicant
Kim et al. “Imaging and therapy of liver fibrosis using bioreducible polyethylenimine/siRNA compleses conjugated with N-acetylglucosamine as a targeting moiety” Biomaterials 34:6504-6514 (2013). cited by applicant
Kim et al., “Specific Binding of Glucose-derivatized Polymers to the Asialoglycoprotein Receptor of Mouse Primary Hepatocytes.” The Journal of Biological Chemistry, vol. 276, No. 38, pp. 35312-35319, Sep. 21, 2001. cited by applicant
Kina et al.,“The Monoclonal Antibody TER-119 Recognizes a Molecule Associated with Glycophorin A and Specifically Marks the Late Stages of Murine Erythroid Lineage,” British Journal of Haematolgy, vol. 109:280-287 (2000). cited by applicant
King et al. “Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell Epitope peptides” Journal of Allergy and Clinical Immunology, vol. 101, Issue 3, Mar. 1998, pp. 397-403. cited by applicant
Kontos et al., “Engineering antigens for in situ erythrocyte binding induces T-cell deletion,” Proceeding of the National Academy Sciences, Dec. 17, 2012, vol. 110, No. 1, p. E60-E68. cited by applicant
Kontos et al., “Improving Protein Pharmacokinetics by Engineering Erythrocyte Affinity,” Molecular Pharmaceutics, 2010, vol. 7, No. 6, p. 2141-2147. cited by applicant
Kontos, “Engineering Erythrocyte Affinity for Improved Pharmacokinetics and Immune Tolerogenesis”, Thesis, 106 Pages (Jun. 23, 2011). cited by applicant
Kopecek et al. “HPMA copolymers: Origins, early developments, present, and future.” Advanced Drug Delivery Reviews 62, (2010) pp. 122-149. cited by applicant
Kravtzoff et al., “Tolerance Evaluation of L-asparaginase loaded in red blood cells,” 1996, Eur J Clin Pharmacol, vol. 51: 221-225. cited by applicant
Krebber et al., “Reliable Cloning of Functional Antibody Variable domains from Hybridomas and Spleen Cell Repertoires Employing a Reengineered Phage Display System,” Journal of Immunological Methods, vol. 201 :35-55 (1997). cited by applicant
La Rosa, et al., “The Innate Immune System in Allograft Rejection and Tolerance,” J. Immunol., 2007, 178:7503-7509. cited by applicant
Langer et al., “Optimization of the Rreparation Process for Human Serum Albumin (HSA) Nanoparticles,” International Journal of Pharmaceutics, 257:169-180, (2003). cited by applicant
Lee et al., “Aptamers as Molecular Recognition Elements for Electrical Nanobiosensors,” Analytical and Bioanalytical Chemistry, 390:1023-1032, (2008). cited by applicant
Lee et al., “Signaling pathways downstream of pattern—recognition receptors and their cross talk,” Annual Review of Biochemistry, vol. 76:447-480 (Feb. 28, 2007). cited by applicant
Lehrman et al., “The Binding of Fucose-containing Glycoproteins by Hepatic Lectins” The Journal of Biological Chemistry Jun. 5, 1986; 261, 7426-7432. cited by applicant
Lepenies et al., “Targeting C-type lectin receptors with multivalent carbohydrate ligands.” Adv. Drug Deliv. Rev. (2013). cited by applicant
Li et al., “Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10pproducing suppressive CD4+ T cells,” Jan. 2, 2012, Journal of Experimental Medicine 209, 109-121 (2012). cited by applicant
Liu et al. “Hapten may play an important role in food allergen-related intestinal immune inflammation,” North American Journal of Medical Sciences, vol. 3. No. 3. (Mar. 2011). cited by applicant
Liu et al.,“Immune tolerance after delivery of dying cells to dendritic cells in situ,” Journal of Experimental Medicine, vol. 196(8): 1091-1097 (Oct. 21, 2002). cited by applicant
Liu et al.,“Functional Nucleic Acid Sensors”, Chemical Reviews, 109(5):1948-1998, (May 2009). cited by applicant
Loma et al., “Multiple Sclerosis: Pathogenesis and Treatment” Department of Neurology, Curr. NeuropharmacOLOGY, 9:409-416, Year 2011. cited by applicant
Lorentz et al., “Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase.” Sci. Adv. 2015. cited by applicant
Luo et al., “ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms,” Proceedings of National Academy of Science, vol. 105(38):14527-14532 (Sep. 23, 2008). cited by applicant
Lutolf et al.,“Synthesis and Physicochemical Characterization of End-Linked Poly(ethylene glycol)-co-peptide Hydrogels Formed by Michael-Type Addition,” Biomacromolecules, 4:713-722, (Feb. 1, 2003). cited by applicant
Lutolf et al.,“Systematic modulation of Michael-type reactivity of thiols through the use of charged amino acids,” Bioconjugate Chemistry vol. 12(6):1051-1056 (2001). cited by applicant
Lutterotti, A. et al., “Antigen-Specific Tolerance by Autologous Myelin Peptide-Coupled Cells: A Phase 1 Trial in Multiple Sclerosis,” Science Translational Medicine 5, 188ra75-188ra75 (2013). cited by applicant
Magnani et al., “Red blood cells as an antigen-delivery system,” Biotechnol Appl Biochem. Oct. 1992;16(2):188-94. cited by applicant
Maluccio et al., “Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma-” Journal of Vascular and Interventional Radiology, vol. 19(6):862-869 (2008). cited by applicant
Mamidyala, et al., “Glycomimetic Ligands for the Human Asialoglycoprotein Receptor”, Journal of the American Chemical Society, Jan. 24, 2012, vol. 134, p. 1978-1981. cited by applicant
Manidyala, S. et al, “Glycomimetic ligands for the human asialoglycoprotein receptor” J. Am Chem. Soc. Feb. 1, 2012, 134(4), pp. 1978-1981. cited by applicant
Maynard et al., “Antibody engineering,” Annual Review of Biomedical Engineering, vol. 2:339-376 (2000). cited by applicant
Meager et al., “Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and or myasthenia gravis” Clinical and Experimental Immunology, Wiley-Blackwell Publishing Ltd, GB, vol. 132, No. 1, Apr. 1, 2003. cited by applicant
Medina et al., “Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands” Advanced Healthcare Materials, vol. 2, Issue 10, pp. 1337-1350, Oct. 2013. cited by applicant
Meyer et al. Metformin and Insulin in Type 1 Diabetes; Diabetes Care 26:1655-1656, Year: 2003. cited by applicant
Miller et al.,“Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease,” Nature Reviews Immunology 7(9):665-677, (Sep. 2007). cited by applicant
Moghimi et al.,“Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties,” Progress in Lipid Research, vol. 42(6):463-478 (2003). cited by applicant
Mohandas et al.,“Red cell membrane: past, present, and future,” Blood, vol. 112(10):3939-3948(Nov. 15, 2008). cited by applicant
Moreau et al, “PEPOP: Computational design of immunogenic peptides” BioMed Central, Jan. 30, 2008, 15 pages. cited by applicant
Mueller,“Mechanisms maintaining peripheral tolerance,” Nature Immunology, vol. 11(1):21-27 (Jan. 2010). cited by applicant
Murphy, “Antigen Recognition by B-Cell and T-cell Receptors,” 2012, Janeway's Immuno Biology, 8th Edition, Chapter 4, Garland Science Taylor & Francis Goup, London and New York. cited by applicant
Murray et al.,“The Mouse Immune Response to Carrier Erythrocyte Entrapped Antigens,” Vaccine, 24:6129-6139, (2006). cited by applicant
Muzykantov, “Drug Delivery by Red Blood Cells: Vascular Carriers Designed by Mother Nature”, Expert Opinion Drug Delivery, 7(4 ):403-427, (Apr. 2010). cited by applicant
Nardin et al., “How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells,” Mol. Immunol. cited by applicant
Nishikawa et al. “Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties” The American journal of physiology Jun. 1995; 268(5 Pt 1):G849-56, Abstract. cited by applicant
O'Neil et al., “Extracellular matrix binding mixed micelles fordrug delivery applications,” Journal of Control Release, vol. 137(2):146-151, (Mar. 27, 2009). cited by applicant
Parmeggiani et al., “Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core,” Journal of Molecular Biology, vol. 376(5):1282-1304 (2008). cited by applicant
Pasut et al.,“PEG conjugates in clinical development oruse as anticancer agents: An overview,” Advanced Drug Delivery Reviews, vol. 61 (13):1177-1188 (2009). cited by applicant
Qin et al., “Galactosylated N-2-Hydroxypropyl Methacrylamide-b-N-3-Guanidinopropyl Methacrylamide Block Copolymers as Hepatocyte-Targeting Gene Carriers,” Bioconjugate Chem. 22:1503-1512 (2011). cited by applicant
Qin, et al., Preparation and bioactivity of anti-hum red blood cell ScFv and CSFV E@ bifunctional fusion protein, Chin J. Biotech 2010, Jan. 25: 26(1): 28-34, Chinese Journal of Biotechnology (2010). cited by applicant
Reddy et al., “Exploiting lymphatic transport and complement activation in nanoparticle vaccines,” Nature Biotechnology, vol. 25(10):1159-1164 (Oct. 2007). cited by applicant
Reddy et al., “In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles,” Journal of Controlled Release, vol. 112(1):26-34, (Mar. 10, 2006). cited by applicant
Reinagel et al., “The Primate Erythrocyte Complement Receptor (CR1) as a Priveleged Site: Binding of Immunoglobulin G to Erythrocyte CR1 Does Not Target Erythrocytes for Phagocytosis,” 1997, Blood, vol. 89: p. 1068-1077. cited by applicant
Rice et al., “Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptides,” Protein Engineering, Design & Selection, vol. 21(7):435-442 (2008). cited by applicant
Rigopoulou et al., “Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found,” Autoimmunity Reviews, 12 (2012) 260-269. cited by applicant
Rockey et al., “Synthesis and radiolabeling of chelator-RNA aptamerbioconjugates with copper-64 for targeted molecular imaging-” Bioorganic & Medicinal Chemistry, vol. 19(13):4080-4090 (2011). cited by applicant
Ruoslahti et al., “Targeting of drugs and nanoparticles to tumors,” Journal of Cell Biology, vol. 188(6):759-768 (2010). cited by applicant
Rybak et al., “The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases,” Cancer Research, vol. 67(22):10948-10957 (2007). cited by applicant
Saibeni et al., “Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis,” J. Thrombosis and Haemostasis, 4:1510-1516 (2006). cited by applicant
Saint-Lu, N. et al., “Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction,” Allergy, vol. 64(7):1003-1013 (2009). cited by applicant
Sakaguchi et al., “Regulatory T Cells and Immune Tolerance,” Cell 133, May 30, 2008, 775-787. cited by applicant
Sampson, “Aptamers and SELEX: the technology,” World Patent Information, vol. (25):123-129 (2003). cited by applicant
Savla et al., “Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer,” Journal of Controlled Release, vol. 153(1 ):16-22, Feb. 20, 2011. cited by applicant
Schliemann et al., “In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy,” Vascular Blood, vol. 115(3):736-744 (Jan. 21, 2010). cited by applicant
Sehon et al., “Conversion of Antigens to Tolerogenic Derivatives by Conjugation with Monomethoxypolyethylene Glycol”, The Pharmacology and Toxicology of Proteins, pp. 205-219 (1987). cited by applicant
Sehon et al., The Pharmacology and Toxicology of Proteins, Proceedings of Cetus-UCLA Symposium Held at Lake Tahoe, Ca, Feb. 21-28, 1987, Alan r. Liss, Inc.—New York. cited by applicant
Seamons et al. Immune Tolerance to Myelin Proteins (Immunologic Research 2003; 28/3:201-221). cited by applicant
Seymour et al., “Hepatic Drug Targeting: Phase I evaluation of polymer-bound doxorubicin” Journal of Clinical Oncology, vol. 20, No. 6, Mar. 15, 2002, pp. 1668-1676. cited by applicant
Seymour et al., “N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice.” Br. J. Cancer (1991) 63, pp. 859-866. cited by applicant
Shan et al., “Structural Basis for Gluten Intolerance in Celiac Sprue,” Science, 297, 2275 (2002). cited by applicant
Sheridan “Fresh from the biologic pipeline-2009,” Nature Biotechnology, vol. 28(4):307-310 (Apr. 2010). cited by applicant
Silverman et al., “Engineered cystine-knot peptides that bind vβ3 integrin with antibody-like affinities,” Journal of Molecular Biology, vol. 382(4):1064-1075 (Jan. 30, 2009). cited by applicant
Sørensen et al., “Role of sialic acid for platelet life span: exposure of β-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes.” Blood, Aug. 20, 2009. vol. 114, No. 8. cited by applicant
Spitzer et al., “ScFv-Mediated in Vivo Targeting of DAF to Erythrocytes Inhibits Lysis by Complement,” Molecular Immunology, vol. 40:911-919 (Oct. 30, 2003). cited by applicant
St. Clair et al., “New Reagents on the Horizon for Immune Tolerance,” Sep. 20, 2006, Annu. Rev. Med. 2007. 58:329-46. cited by applicant
Staud et al., “Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation” Biochimica et Biophysica Acta May 1999; 1427(2):183-192, Abstract. cited by applicant
Steiner et al., “Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display,” Journal of Molecular Biology, vol. 382(5):1211-1227 (2008). cited by applicant
Sun, et al, “Comparison between Ovalbumin and Ovalbumin Peptide 323-339 Responses in Allergic Mice: Humoral and Celluler Aspects,” Scandinavian Journal of Immunology, vol. 71: 329-335 (Jan. 2010). cited by applicant
Supplementary European Search Report from corresponding PCT Application No. PCT/US2011047078, 21 Pages, dated Jan. 22, 2014. cited by applicant
Taneja et al., “Lessons from animal models for human autoimmune diseases,” Sep. 1, 2001, Nature Immunology, vol. 2, No. 9, 781-784 (Sep. 2001). cited by applicant
Taylor et al., “Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity”, Protein Engineering, Design & Selection, vol. 23, No. 4 pp. 251-260, 2010. cited by applicant
Thijssen et al., “Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy-”, Proceeding of the Natinoal Academy Sciences, vol. 103(43):15975-15980 (2006). cited by applicant
Teitelbaum et al., Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Pro. Natl. Acad. Sci. USA vol. 96, pp. 3842-3847, Mar. 1999. cited by applicant
Thomson et al., “Antigen-presenting cell function in the tolerogenic liver environment,” National Reviews Immunology, vol. 10(11):753-766 (Nov. 2010). cited by applicant
Tobio et al., “Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration,” Pharmaceutical Research, 15(2):270-275, (1998). cited by applicant
Trahtenherts, A. et al, “An internalizing antibody specific for the human asialoglycoprotein receptor” Hybridoma, vol. 28, No. 4, Aug. 1, 2009. cited by applicant
Tye-Din, et al. “Comprehensive, Quantitive Mapping of T Cell Epitopes in Gluten in Celiac Disease”, www.ScienceTranslationalMedicine.org, Jul. 21, 2010, vol. 2 Issue 41, in 14 pages. cited by applicant
Turley et al., “Prospects for Antigen-Specific Tolerance Based Therapies for the Treatment of Multiple Selerosis,” Results and Problems in Cell Differentiation, 51 :217-235, (2010). cited by applicant
Updike et al., “Infusion of red blood cell-loaded asparaginase in monkey: Immunologic, metabolic, and toxicologic consequences,” 1983, J Lab Clin Med, vol. 101(5): p. 679-691. cited by applicant
Van Der Vlies et al., “Synthesis of pyridyl disulfide-functionalized nanopa rticles for conjugating thiol-containing small molecules, peptides, and proteins,” Bioconjugate Chemistry, vol. 21 (4):653-662 (2010). cited by applicant
Velluto et al., “PEG-b-PPS Diblock Copolymer Aggregates for Hydrophobic Drug Solubilization and Release: Cyclosporin A as an Example,” Molecular Pharmaceutics, 11 Pages, (May 2, 2008). cited by applicant
Vogl et al., “Reviewon transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications,” European Journal Radiology, vol. 72(3):505-516 (2009). cited by applicant
Walker et al., “Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon,” Protein Engineering Design & Selection, vol. 23(4):271-278 (2010). cited by applicant
Wan, “Regulatory T cells: immune suppression and beyond,” May 1, 2010, Cell Mol Immunol. May 2010; 7(3):204-210. cited by applicant
Wang et al., “Synthesis and Micellization of Thermoresponsive Galactose-Based Diblock Copolymers,” J Polymer Sci. 49:3280-3290 (2011). cited by applicant
Weisser et al., “Applications of single-chain variable fragment antibodies in therapeutics and diagnostics,” Biotechnology Advances, vol. 27(4):502-520 (2009). cited by applicant
Wilson et al., “Rapid Whole Blood Assay For HIV-1 Seropositivity Using An Fab-Peptide Conjugate,” Journal of Immunological Methods, vol. 138:111-119 (1991). cited by applicant
Yamazaki et al., “CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells,” Journal of Immunology, vol. 181 (10):6923-6933 (2008). cited by applicant
Yeste Ada et al: “Antigen Microarrays for the Study of Autoimmune Diseases”, Clinical Chemistry, vol. 59, No. 7, Jul. 2013 (Jul. 2013), pp. 1036-1044, ISSN: 0009-9147(print). cited by applicant
Yoo et al., “N-Acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein.” Bioconjugate Chemistry, vol. 24, No. 12, Dec. 18, 2013, pp. 2088-2103. cited by applicant
Zaitsev et al., “Targeting of a Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis”, The Journal of Pharmacology and Experimental Therapeutics, 332(3):1022-1031 and 976 (Nov. 30, 2009). cited by applicant
Zhao, X. et al “Construction and characterization of an anti-asialoglycoprotein receptor single-chain variable-fragment-targeted melittin” Biotechnology and Applied Biochemistry, Nov.-Dec. 2011; 58(6): pp. 405-411. cited by applicant
Zhong et al., “Ligand-directed Reduction-Sensitive Shell-Sheddable Biodegradable Micelles Actively Deliver Doxorubicin into the Nuclei of Target Cancer Cells,” Biomacromalecules 14:3723-3730 (2013). cited by applicant
Baker, et al. “Hybrid Insulin Peptides are Autoantigens in Type 1 Diabetes”, Diabetes, Sep. 2019, vol. 68, pp. 1830-1840. cited by applicant
Dominguez-Soto, et al., “The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells” www.bloodjournal.org. Immunobiology, Jun. 15, 2007, vol. 109, No. 12, pp. 5337-5345. cited by applicant
Gurwitz, “Peptide Mimetics: Fast-Forward Look” Drug Development Research 78:231-235, Year 2017. cited by applicant
Kontos, et al., “Engineering antigen-specific immunological tolerance”, www.sciencedirect.com, Current Opinion in Immunology, Jul. 8, 2015, 35:80-88. cited by applicant
Nakayama, et al., “Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes”, Frontiers in Immunology, Mar. 8, 2019, vol. 10, pp. 1-7. cited by applicant
Rajpal, Arvind, et al. “A general method for greatly improving the affinity of antibodies by using combinatorial libraries”, PNAS, www.pnas.org/cgi/doi/10.1073/pnas.0503543102, vol. 102 No. 24, pp. 8466-8471, Jun. 14, 2005. cited by applicant
Shen “A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy” Pharmacological Research 64 (2011) 410-419. cited by applicant
Wilson, D.B., “Kent et al. Replying to: D.B. Wilson”, Nature, 438, 2005. cited by applicant
Wu, Herren, “Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies”, Methods in Molecular Biology, vo. 207: Recombinant Antibodies for Cancer Therapy: Methods and Protocols, Tolowa, NJ, pp. 197-212, Jan. 1, 2003. cited by applicant
https://en.wikipedia.org/wiki/Tenecteplase, accessed Apr. 13, 2020, printed Apr. 23, 2020 in 4 pages. cited by applicant
https://en.wikipedia.org/wiki/Reteplase accessed Apr. 13, 2020, printed Apr. 23, 2020 in 2 pages. cited by applicant
Caja et al., “Antibodies in celiac disease: implications beyond diagnostics,” Cellular & Molecular Immunology (2011) 8, 103-109. cited by applicant
Clements et al., “The Crystal Structure of Myelin Oligodendrocyte Glycoprotein, a key autoantigen in multiple sclerosis,” Proc. Natl. Acad. Sci. (PNAS) vol. 100: 11059-11064 (Sep. 2003). cited by applicant
Lobst et al., “Selective Sugar Binding to the Carbohydrate Recognition Domains of the Rat Hepatic and Macrophage Asialoglycoprotein Receptors.” The Journal of Biological Chemistry, vol. 271, No. 12, Issue Mar. 22, 1996, 6686-6693. cited by applicant
Mitea, C. et al., “A Universal Approach to Eliminate Antigenic Properties of Alpha-Gliadin Peptides in Celiac Disease.” PLoS One, vol. 5, Issue 12, e15637, pp. 1-9, Dec. 2010. cited by applicant
Stern et al., “Promoting Tolerance to Proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells,” Proc. Natl. Acad. Sci. (PNAS) vol. 107:17280-17285, (Oct. 2010). cited by applicant
Martini, S., Nielsen, M., Peters, B. et al. The Immune Epitope Database and Analysis Resource Program 2003-2018: reflections and outlook. Immunogenetics 72, 57-76 (2020). cited by applicant
https://en.wikipedia.org/wiki/Tenecteplase, accessed Oct. 23, 2020, printed Nov. 30, 2020 in 4 pages. cited by applicant
https://en.wikipedia.org/wiki/Reteplase accessed Oct. 23, 2020, printed Nov. 30, 2020 in 2 pages. cited by applicant
htltps://www.merriam-webster.com/dictionary/immunogenic, accessed Oct. 23, 2020, printed Nov. 30, 2020 in 7 pages. cited by applicant
Sigma-Aldrich, “RAFT Agents,” available online at https://www.sigmaaldrich.com/materials-science/material-science-products.html? TablePage=103936134, 4 pages (accessed on Sep. 21, 20) (Year: 2020). cited by applicant
Benaglia et al. “Searching for More Effective Agents and Conditions for the RAFT Polymerization of MMA: Influence of Dithioester Substituents, Solvent, and Temperature” Macromolecules 2005, 38, 3129-3140 (Year: 2005). cited by applicant
Boyer et al. “Bioapplications of RAFT Polymerization”. Chem. Rev. 2009, 109, 5402-5436 (Year: 2009). cited by applicant
Calvaresi and Hergenrother. “Glucose conjugation for the specific targeting and treatment of cancer”; Chem Sci. Jun. 2013; 4(6): 2319—2333 (Year: 2013). cited by applicant
Cheremisinoff. Condensed Encyclopedia of Polymer Engineering Terms, Butterworth-Heinemann, 2001, pp. 39-81. (Year: 2001). cited by applicant
Karim et al. “Hepatic expression and cellular distribution of the glucose transporter family”; World J Gastroenterol Dec. 14, 2012; 18(46): 6771-6781 (Year: 2012). cited by applicant
Klebe. “Optimization of Lead Structures”, Drug Design, Springer-Verlag Berlin Heidelberg 2013, pp. 153-171. (Year: 2013). cited by applicant
Moad et al., “Mechanism and Kinetics of Dithiobenzoate-Mediated RAFT Polymerization—Status of the Dilemma.” Macromolecular Journals Chem. Phys. 2014, 215: 9-26. cited by applicant
Moss et al. “Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure”, Pure & Appl. Chem., vol. 67, Nos. 819, pp. 1307-1375, 1995 (Year: 1995). cited by applicant
Wang et al in “Diagnostic imaging and therapeutic application of nanoparticles targeting the liver”; J. Mater. Chem. B, 2015, 3, 939. (Year: 2015). cited by applicant
Sigma-Aldrich, “RAFT Agents,” available online at https://www.sigmaaldrich.com/materials-science/material-science-products.html? TablePage=103936134, 4 pages (accessed on Sep. 21, 2020) (Year: 2020). cited by applicant
Wilcock, H. et al. “End Group Removal and Modification of RAFT polymers,” Polymer Chemistry, vol. 1, Jan. 1, 2010, pp. 149-157. cited by applicant
Primary Examiner: Gebreyesus, Kagnew H
Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear LLP
رقم الانضمام: edspgr.11246943
قاعدة البيانات: USPTO Patent Grants
الوصف
الوصف غير متاح.